- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00007657
Kliniske resultater ved anvendelse af revaskularisering og aggressiv lægemiddelevaluering
CSP #424 - Kliniske resultater ved brug af revaskularisering og aggressiv lægemiddelevaluering
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Primær hypotese: Strategien med PCI plus intensiv medicinsk terapi vil være overlegen i forhold til intensiv medicinsk terapi alene med hensyn til at reducere dødeligheden af alle årsager eller ikke-fatal MI hos patienter med dokumenteret myokardieiskæmi, som opfylder en AHA-taskforce klasse I indikation for PCI.
Sekundære hypoteser: Ressourceudnyttelse og QOL sammenligninger og hospitalsindlæggelse for akutte koronare syndromer vil være overlegne i PCI plus medicinsk terapi sammenlignet med medicinsk terapi alene.
Primære udfald: Alle forårsager dødelighed, ikke-dødelig MI.
Interventioner: Alle patienter vil blive behandlet med intensiv medicinsk terapi. Derudover vil halvdelen af dem modtage perkutan koronar intervention (PCI).
Studieresumé: COURAGE-forsøget er et storstilet, multicenter, randomiseret kontrolleret forsøg, der sammenligner medicinsk terapi og PCI plus medicinsk terapi, der er drevet til "hårde" kliniske endepunkter. Patienter, der er berettiget til inklusion i COURAGE, vil omfatte alle undtagen meget højrisiko-patienter og vil omfatte patienter med kronisk angina pectoris (Canadian Cardiovascular Society [CCS] Klasse I-III), nylig ukompliceret MI og asymptomatisk (eller "tavs") myokardie iskæmi. Patienter kan have enkelt- eller multikar-koronararteriesygdom og kan have haft tidligere bypassoperationer eller PCI. Vi fremskriver kumulative 3-årige hændelsesrater på henholdsvis 16,4 % og 21 %, hvilket giver en absolut forskel på 4,6 % eller en relativ forskel på 22 %. Med en minimumsvarighed af opfølgning på 2 1/2 år, maksimalt 7 år, ved brug af en tosidet signifikanstest på 0,05-niveauet, og under antagelse af en 3 % crossover rate, derefter 2 % og derefter 1 % hver for 2 år fra medicin til PCI, og årlig tab til opfølgningsrate på 1 %, indikerer disse hændelsesrater, at en stikprøvestørrelse på 2.270 vil være nødvendig for at teste hypotesen med 85 % effekt. Femten VA, 19 amerikanske ikke-VA og 16 canadiske websteder er tilmeldt undersøgelsen. Den planlagte undersøgelsesvarighed var 7 år med 4 1/2 års patientindtagelse og 2 1/2 - 7 års opfølgning. Undersøgelsen begyndte i januar 1999 og indskrivningen begyndte i juni 1999. Data and Safety Monitoring Board godkendte at reducere stikprøvestørrelsen til 2.270 forsøgspersoner baseret på at øge længden af randomisering og opfølgning og opdatere definitionen af MI til at inkludere biomarkørpositiv (troponin) ACS. Tilmeldingen er fuldført med 2.287 tilmeldte patienter.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Hospital - Calgary, Alberta - Can
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St Paul's Hospital, Vancouver - British Columbia
-
-
New Brunswick
-
St. John, New Brunswick, Canada, E2L 4L2
- St. John Regional Hospital Facility
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Queen Elizabeth Ii Hsc, Halifax, Nova Scotia - Can
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton General Hospital - Hamilton, Ont - Can
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Ctr - London, Ont - Can
-
Mississauga, Ontario, Canada, L5B 2P7
- Trillium Health Care
-
Sudbury, Ontario, Canada, P3E 2N8
- Sudbury Regional Hospital - Sudbury, Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook HSC - Toronto, Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael'S Hospital, Toronto, Ontario - Can
-
-
Quebec
-
Montreal, Quebec, Canada, H4J1C5
- Hopital du Sacre-Coeur de Montreal
-
Montreal, Quebec, Canada, H1T 1C8
- Montreal Heart Institute - Montreal, Quebec - Can
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85259
- Mayo Clinic Arizona
-
-
Arkansas
-
No. Little Rock, Arkansas, Forenede Stater, 72114-1706
- Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
-
-
California
-
Los Angeles, California, Forenede Stater, 90027
- Southern CA Kaiser Permanente Medical Group
-
Sacramento, California, Forenede Stater, 95655
- VA Northern California HCS
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06102-5037
- Hartford Hospital
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19718
- Christiana Care Health Systems-Newark, DE
-
-
Florida
-
Melbourne, Florida, Forenede Stater, 32901
- MIMA Century Research Associates - Melbourne, FL
-
Tampa, Florida, Forenede Stater, 33612
- James A. Haley Veterans Hospital, Tampa
-
-
Georgia
-
Decatur, Georgia, Forenede Stater, 30033
- Atlanta VA Medical and Rehab Center, Decatur
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Jesse Brown VAMC (WestSide Division)
-
-
Iowa
-
Davenport, Iowa, Forenede Stater, 52803-2498
- Genesis Medical Center
-
Iowa City, Iowa, Forenede Stater, 52246-2208
- VA Medical Center, Iowa City
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40502
- VA Medical Center, Lexington
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- VA Maryland Health Care System, Baltimore
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02130
- VA Medical Center, Jamaica Plain Campus
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48113
- VA Ann Arbor Healthcare System
-
Detroit, Michigan, Forenede Stater, 48201
- John D. Dingell VA Medical Center, Detroit
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic Rochester - Rochester, MN
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64128
- VA Medical Center, Kansas City MO
-
St Louis, Missouri, Forenede Stater, 63106
- VA Medical Center, St Louis
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87108-5153
- New Mexico VA Health Care System, Albuquerque
-
-
New York
-
New York, New York, Forenede Stater, 10010
- New York Harbor HCS
-
Rochester, New York, Forenede Stater, 14642-8679
- University of Rochester Strong Memorial Hospital
-
Syracuse, New York, Forenede Stater, 13210
- VA Medical Center, Syracuse
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- VA Medical Center, Durham
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- VA Medical Center, Cleveland
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- VA Medical Center, Oklahoma City
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97201
- VA Medical Center, Portland
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- VA Medical Center, Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38104
- VA Medical Center, Memphis
-
Nashville, Tennessee, Forenede Stater, 37212-2637
- VA Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Michael E. DeBakey VA Medical Center (152)
-
San Antonio, Texas, Forenede Stater, 78229
- VA South Texas Health Care System, San Antonio
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98108
- VA Puget Sound Health Care System, Seattle
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inklusionskriterier:
- Patienter, der er berettiget til inklusion i COURAGE, vil omfatte alle undtagen meget højrisiko-patienter og vil omfatte patienter med kronisk angina pectoris (Canadian Cardiovascular Society [CCS] Klasse I-III), ukompliceret MI, nedkølet ACS og asymptomatiske (eller "tavse" ") myokardieiskæmi.
- Patienter kan have enkelt- eller multikar-koronararteriesygdom og kan have haft tidligere bypassoperationer eller PCI.
Det er vigtigt at understrege, at så mange typer CAD-patienter som muligt - som afspejler spektret af patienter, man støder på i nutidig klinisk praksis - vil blive tilmeldt COURAGE.
Ekskluderingskriterier:
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 1
Perkutan koronar intervention (PCI) plus intensiv medicinsk behandling
|
|
Aktiv komparator: 2
Intensiv medicinsk terapi
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: William E. Boden, VA South Texas Health Care System, San Antonio
Publikationer og nyttige links
Generelle publikationer
- Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15. doi: 10.1016/j.jacc.2013.01.044.
- Mancini GBJ, Maron DJ, Hartigan PM, Spertus JA, Kostuk WJ, Berman DS, Teo KK, Weintraub WS, Boden WE; COURAGE Trial Research Group. Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. J Am Coll Cardiol. 2019 Apr 30;73(16):2049-2058. doi: 10.1016/j.jacc.2018.11.067.
- Weintraub WS, Hartigan PM, Mancini GBJ, Teo KK, Maron DJ, Spertus JA, Chaitman BR, Shaw LJ, Berman D, Boden WE. Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005079. doi: 10.1161/CIRCOUTCOMES.118.005079.
- Maron DJ, Mancini GBJ, Hartigan PM, Spertus JA, Sedlis SP, Kostuk WJ, Berman DS, Teo KK, Weintraub WS, Boden WE; COURAGE Trial Group. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. J Am Coll Cardiol. 2018 Nov 6;72(19):2297-2305. doi: 10.1016/j.jacc.2018.08.2163.
- Zhang Z, Jones P, Weintraub WS, Mancini GBJ, Sedlis S, Maron DJ, Teo K, Hartigan P, Kostuk W, Berman D, Boden WE, Spertus JA. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e003971. doi: 10.1161/CIRCOUTCOMES.117.003971.
- Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE; COURAGE Trial Investigators. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med. 2015 Nov 12;373(20):1937-46. doi: 10.1056/NEJMoa1505532.
- Mancini GBJ, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. JACC Cardiovasc Interv. 2014 Feb;7(2):195-201. doi: 10.1016/j.jcin.2013.10.017. Epub 2014 Jan 15.
- Mancini GB, Hartigan PM, Bates ER, Chaitman BR, Sedlis SP, Maron DJ, Kostuk WJ, Spertus JA, Teo KK, Dada M, Knudtson M, Berman DS, Booth DC, Boden WE, Weintraub WS. Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial. Am Heart J. 2013 Sep;166(3):481-7. doi: 10.1016/j.ahj.2013.07.007. Epub 2013 Aug 2.
- Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol. 2013 Nov 12;62(20):1826-33. doi: 10.1016/j.jacc.2013.07.051. Epub 2013 Aug 21.
- Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB; Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators and Coordinators. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):409-18. doi: 10.1161/CIRCOUTCOMES.113.000139. Epub 2013 Jul 9.
- Maron DJ, Hartigan PM, Neff DR, Weintraub WS, Boden WE; COURAGE Trial Investigators. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial). Am J Cardiol. 2013 Jun 1;111(11):1557-62. doi: 10.1016/j.amjcard.2013.02.005. Epub 2013 Mar 25.
- Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, Dada M, Mancini GB, Hayes SW, O'Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J. 2012 Aug;164(2):243-50. doi: 10.1016/j.ahj.2012.05.018.
- Mancini GB, Hartigan PM, Bates ER, Sedlis SP, Maron DJ, Spertus JA, Berman DS, Kostuk WJ, Shaw LJ, Weintraub WS, Teo KK, Dada M, Chaitman BR, O'Rourke RA, Boden WE; COURAGE Investigators and Coordinators. Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial. Circ Cardiovasc Interv. 2011 Dec 1;4(6):545-52. doi: 10.1161/CIRCINTERVENTIONS.110.960062. Epub 2011 Nov 1.
- Maron DJ, Boden WE, Spertus JA, Hartigan PM, Mancini GB, Sedlis SP, Kostuk WJ, Chaitman BR, Shaw LJ, Berman DS, Dada M, Teo KK, Weintraub WS, O'Rourke RA; COURAGE Trial Research Group. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2011 Jul 5;58(2):131-7. doi: 10.1016/j.jacc.2011.02.046.
- Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):172-82. doi: 10.1161/CIRCOUTCOMES.110.940502. Epub 2011 Feb 8.
- Chaitman BR, Hartigan PM, Booth DC, Teo KK, Mancini GB, Kostuk WJ, Spertus JA, Maron DJ, Dada M, O'Rourke RA, Weintraub WS, Berman DS, Shaw LJ, Boden WE; Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial investigators. Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system? Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):476-83. doi: 10.1161/CIRCOUTCOMES.109.901579. Epub 2010 Jul 27.
- Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58. doi: 10.1016/j.jacc.2009.10.062.
- Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.
- Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG; Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):12-20. doi: 10.1161/CIRCOUTCOMES.108.798462.
- Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE; COURAGE Trial Research Group; Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008 Aug 14;359(7):677-87. doi: 10.1056/NEJMoa072771.
- Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.
- Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26.
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 424
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myokardieiskæmi
-
Sichuan Provincial People's HospitalTilmelding efter invitationRest Gated Myocardial Perfusion Imaging ved hjertesvigtKina
-
Azienda Ospedaliero Universitaria Maggiore della...Università degli Studi del Piemonte Orientale "Amedeo Avogadro"Rekruttering
-
Peking University Third HospitalAfsluttet
-
Stanford UniversitySuspenderetMyocardial brodannelseForenede Stater
-
Izmir Bakircay UniversityAfsluttetMyokardiebro af kranspulsårenKalkun
-
Fondazione Policlinico Universitario Agostino Gemelli...Afsluttet
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiAfsluttetMyokardiebro af kranspulsårenItalien
-
RenJi HospitalAfsluttetSomatisk symptomlidelse | MyokardiebroKina
-
Chinese Academy of Medical Sciences, Fuwai HospitalAfsluttetKoronararteriesygdom | Hypertrofisk kardiomyopati | Myocardial brodannelse
-
Hospital San Carlos, MadridFundacion Investigacion Interhospitalaria CardiovascularRekrutteringMyokardieiskæmi | Vasospastisk angina | Ikke-obstruktiv koronar aterosklerose | Mikrovaskulær koronararteriesygdom | Myocardial brodannelseSpanien
Kliniske forsøg med Intensiv medicinsk terapi
-
Loewenstein HospitalTechnion, Israel Institute of TechnologyRekruttering
-
The First Affiliated Hospital with Nanjing Medical...West China Hospital; Fujian Medical University Union Hospital; Chinese Academy... og andre samarbejdspartnereRekrutteringHjertefejl | Venstre bundt-grenblok | Ikke-iskæmisk kardiomyopatiKina
-
JOTEC GmbHRekrutteringAortadissektion | Intramuralt hæmatom | Akut DeBakey I Dissektion | Akut type A dissektionTyskland
-
Teachers College, Columbia UniversityBurke Medical Research InstituteAfsluttetCerebral Parese | Børn | HemiplegiForenede Stater
-
Nova Scotia Health AuthorityAfsluttetSomatiske symptomer og relaterede lidelser | Intensiv kortvarig dynamisk psykoterapiCanada
-
Toad Medical CorporationUniversity Hospitals Cleveland Medical CenterUkendtDiabetisk fod | PedalsårForenede Stater
-
NYU Langone HealthAfsluttetHemiplegi | Neurologisk skadeForenede Stater
-
Kaohsiung Medical University Chung-Ho Memorial...RekrutteringOveraktiv blære | Interstitiel blærebetændelse | Kvindelig seksuel dysfunktion | StressinkontinensTaiwan
-
Teachers College, Columbia UniversityEmory University; Thrasher Research FundAfsluttetCerebral Parese | Børn | Hemiplegi | PædiatriskForenede Stater
-
University of MinnesotaUniversity of Pittsburgh; Duke University; Oregon Health and Science University og andre samarbejdspartnereAktiv, ikke rekrutterendeLænderygsmerter, mekaniske | Akut smerteForenede Stater